Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Locally Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 348
Testing effectiveness (Phase 2)Ended earlyNCT01528345
What this trial is testing

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 97
Post-approval studies (Phase 4)Study completedNCT03583944
What this trial is testing

Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Inc. 200
Large-scale testing (Phase 3)Study completedNCT00944918
What this trial is testing

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Who this might be right for
Progression-free Survival
AstraZeneca 25
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)UnknownNCT05103917
What this trial is testing

Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Who this might be right for
Triple Negative Breast Cancer
Abbisko Therapeutics Co, Ltd 24
Large-scale testing (Phase 3)Study completedNCT03371017
What this trial is testing

The Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Hoffmann-La Roche 595
Early research (Phase 1)Study completedNCT05002868
What this trial is testing

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Who this might be right for
Solid TumorExtensive-stage Small-cell Lung CancerLocally Advanced Breast Cancer+4 more
Rhizen Pharmaceuticals SA 23
Large-scale testing (Phase 3)Study completedNCT00191438
What this trial is testing

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 300
Early research (Phase 1)Looking for participantsNCT02926690
What this trial is testing

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Who this might be right for
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc. 70
Not applicableActive Not RecruitingNCT04497285
What this trial is testing

Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 600
Large-scale testing (Phase 3)Looking for participantsNCT06998108
What this trial is testing

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Who this might be right for
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc 330
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Study completedNCT00965523
What this trial is testing

Study of E7389 for Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Co., Ltd. 81
Large-scale testing (Phase 3)UnknownNCT05433480
What this trial is testing

BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Betta Pharmaceuticals Co., Ltd. 274
Early research (Phase 1)Looking for participantsNCT07540572
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Who this might be right for
ER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more
IDEAYA Biosciences 160
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Large-scale testing (Phase 3)Looking for participantsNCT06081959
What this trial is testing

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Next Page